Pioglitazone intratympanic gel - Strekin

Drug Profile

Pioglitazone intratympanic gel - Strekin

Alternative Names: Pioglitazone hydrochloride thermogel - Strekin; STR 001; STR001 thermogel; STR001-IT; SUB03834MIG

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Strekin
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hearing loss
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hearing loss

Most Recent Events

  • 15 Nov 2017 Strekin completes a phase II trial in Hearing loss (Prevention) in Germany, Spain (Intratympanic) (EudraCT2015-002672-25)
  • 27 Jun 2017 Phase-III clinical trials in Hearing loss in Czech Republic (Intratympanic) (EudraCT2017-000242-22)
  • 31 May 2017 Strekin plans the phase III RESTORE trial for Hearing loss in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top